Atea (AVIR) director adds 6,100 shares in open-market purchase

Filing Impact

(Neutral)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Atea Pharmaceuticals director Polly A. Murphy reported an open-market purchase of 6,100 shares of Common Stock. The shares were bought on May 18, 2025 at a weighted average price of $4.1715 per share, with individual trade prices ranging from $4.14 to $4.19 per share. Following this transaction, Murphy directly holds 92,145 shares of Atea Pharmaceuticals common stock.

Insider Trade Summary

Net Buyer: 6,100 shares ($25,446)

Net Buy 1 txn

Insider Murphy Polly A.

Role null

Bought 6,100 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	6,100	$4.1715	$25K

Holdings After Transaction: Common Stock — 92,145 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares purchased: 6,100 shares Weighted average price: $4.1715 per share Trade price range: $4.14–$4.19 per share +2 more

5 metrics

Shares purchased 6,100 shares Open-market buy of Common Stock on May 18, 2025

Weighted average price $4.1715 per share Average purchase price for 6,100 shares

Trade price range $4.14–$4.19 per share Range of individual execution prices on transaction date

Shares owned after transaction 92,145 shares Direct holdings following the reported purchase

Net buy direction 6,100 net shares bought transactionSummary shows net-buy activity

Key Terms

open-market purchase, weighted average price, Common Stock, Form 4

4 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"This purchase was reported on a Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/20/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Murphy Polly A.

(Last)

(First)

(Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON

MASSACHUSETTS

02110

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/18/2025		P		6,100	A	$4.1715⁽¹⁾	92,145	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $4.14 to $4.19 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Andrea Corcoran, as Attorney-in-Fact for Polly A. Murphy	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Atea Pharmaceuticals (AVIR) director Polly A. Murphy do in this Form 4?

Director Polly A. Murphy bought 6,100 shares of Atea Pharmaceuticals Common Stock in an open-market transaction. This purchase was reported on a Form 4 and reflects a personal increase in her direct equity position in the company.

How many Atea Pharmaceuticals (AVIR) shares does Polly A. Murphy own after this transaction?

After the reported purchase, Polly A. Murphy directly owns 92,145 shares of Atea Pharmaceuticals Common Stock. This figure represents her direct holdings as of the transaction date disclosed in the Form 4 filing with the Securities and Exchange Commission.

What price did Polly A. Murphy pay for Atea Pharmaceuticals (AVIR) shares?

Murphy paid a weighted average price of $4.1715 per share for 6,100 Atea Pharmaceuticals shares. The Form 4 notes individual trades occurred between $4.14 and $4.19 per share, reflecting multiple executions within that price range.

Was Polly A. Murphy’s Atea (AVIR) transaction an open-market purchase?

Yes, the Form 4 characterizes the transaction as an open-market purchase of Common Stock. This is indicated by transaction code “P” and the description “Purchase in open market or private transaction,” confirming it as a straightforward buy in the market.

Does the Form 4 for Atea (AVIR) mention how trade prices were calculated?

The filing explains that the reported $4.1715 figure is a weighted average price. Shares were purchased in multiple transactions between $4.14 and $4.19, and the reporting person offers to provide detailed trade-by-trade pricing information upon request.